Aplastic Anemia Clinical Pathway — All Settings
Aplastic Anemia Clinical Pathway — All Settings
Goals
- Improving clinician recognition of patients with aplastic anemia
- Timely diagnosis, completion of pre-treatment laboratory evaluations, and initiation of treatment
- Improved patient outcomes by standardizing assessment of treatment response and initiation of 2nd treatment when indicated.
Metrics
- % of patients that have definitive treatment plan in place by 4 weeks from diagnosis
- % of patients that have BM aspirate/biopsy completed with proper cytogenetic assessments, including karyotype analysis and SNP array at diagnosis
- % of patients with severe aplastic anemia that have HLA typing, telomere testing, PNH testing, and chromosomal breakage testing completed and resulted by 4 weeks from diagnosis.
- % of patients who remain transfusion dependent or with an ANC < 500 by 6 months post treatment.
- % of patients who undergo repeat BM aspirate/biopsy at 3 and 12 months post-IST.
- % of patients who undergo PNH testing at 1 year post-transplant.
- % of patients who have dose adjustment of Cyclosporine after Voriconazole is discontinued.
Notes
- BM: Bone marrow
- SNP: Single-nucleotide polymorphism
- HLA: Human Leukocyte antigen
- PNH: Paroxysmal nocturnal hemoglobinuria
- IST: Immunosuppressive therapy